BMS 906024

Drug Profile

BMS 906024

Alternative Names: BMS-906024

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Acute lymphoblastic leukaemia; T cell lymphoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in T-cell-lymphoma(Combination therapy, Second-line therapy or greater) in France (IV)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in T-cell-lymphoma(Combination therapy, Second-line therapy or greater) in Germany (IV)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in T-cell-lymphoma(Combination therapy, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top